In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications
similar to those produced by the SARS coronavirus in the 2002-2003 epidemic. This new disease
was named COVID-19 and the causative virus SARS-CoV-2. The SARS-CoV-2 virus, enters the
airway and binds, by means of the S protein on its surface to the membrane protein ACE2 in
type 2 alveolar cells. The S protein-ACE2 complex is internalized by endocytosis leading to a
partial decrease or total loss of the enzymatic function ACE2 in the alveolar cells and in
turn increasing the tissue concentration of pro-inflammatory angiotensin II by decreasing its
degradation and reducing the concentration of its physiological antagonist angiotensin 1-7.
High levels of angiotensin II on the lung interstitium can promote apoptosis initiating an
inflammatory process with release of proinflammatory cytokines, establishing a self-powered
cascade, leading eventually to ARDS. It has recently been proposed the tentative use of
agents such as losartan and telmisartan as alternative options for treating COVID-19 patients
prior to development of ARDS. The present study is an open-label randomized phase II clinical
trial for the evaluation of telmisartan in COVID-19 patients. Briefly, patients with
confirmed diagnosis of SARS-CoV-2, will be randomized to receive 80 mg/12h of telmisartan
plus standard care or standard care alone aand will be monitored for development of systemic
inflammation and acute respiratory distress syndrome. Other variables regarding lung function
and cardiovascular function will also be evaluated.
Phase:
Phase 4
Details
Lead Sponsor:
Laboratorio Elea Phoenix S.A. Laboratorio Elea S.A.C.I.F. y A.
Collaborators:
Carlos R. Rojo, MD Facultad de Medicina, Universidad de Buenos Aires, UBA